thebench.bio #1 Ecosystem for the Bio-Tech Industry
All Molecular Biology questions

Question 7 of 9 Intermediate Troubleshooting

How would you distinguish a transcriptional change from altered RNA stability after a drug treatment?

Short answer

Total mRNA abundance reflects both the rate of transcription and the rate of degradation. Measure newly synthesised RNA and decay kinetics separately before claiming that a drug acts at transcription.

Why

At approximate steady state, RNA abundance is proportional to synthesis divided by clearance. A larger qPCR or RNA-seq signal therefore does not identify which parameter changed. Even transient time courses can mix synthesis and decay effects.

Intronic reads and nascent RNA assays are helpful but measure related, not identical, processes.

How to work it through

  1. Use matched treated and control samples over several early and late time points.
  2. Quantify mature RNA and nascent RNA using a suitable 4sU pulse, run-on or equivalent assay.
  3. Estimate disappearance of labelled RNA in a pulse-chase if half-life matters.
  4. Evaluate viability, spike-ins, RNA recovery and stable reference genes.
  5. Fit a simple synthesis-decay model only if the sampling schedule supports its assumptions.

An example

If mature mRNA doubles while new-RNA incorporation remains similar and labelled transcript disappears more slowly, increased stability is more plausible than promoter activation. If nascent signal rises immediately before total RNA rises, a transcriptional mechanism gains support.

Where the answer stops holding

Label uptake may change with treatment. Transcriptional inhibitors can themselves perturb decay. Non-steady-state responses, altered splicing, isoforms and cell-mixture shifts break simplistic inference.

A reporter or promoter mark alone does not quantify endogenous transcription.

A strong answer covers

  • Total mRNA abundance reflects both the rate of transcription and the rate of degradation
  • Measure newly synthesised RNA and decay kinetics separately before claiming that a drug acts at transcription
  • Use matched treated and control samples over several early and late time points

Common mistakes

  • Calling every fold-change in total RNA a transcriptional change
  • Using one time point
  • Treating transcription-inhibitor chase kinetics as unperturbed biology